Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Cheers Northeast, hopefully everything is set for a stellar year ahead, and just need some good news from Eric to get the ball rolling and the sp heading North. Gl :-)
Science 20 DEC 2023
Sirtuin 6 Activation Reverses Age-Related DNA Repair Decline
"In conclusion, the findings presented here support the hypothesis that the efficiency of DNA damage repair declines with age in chondrocytes and that SIRT6 activation improves repair both in response to an acute irradiation challenge and in the context of age-related damage accumulation. These results emphasize the critical role of SIRT6 in DNA repair and support further studies investigating the use of MDL-800 (or alternative SIRT6 activators) in mitigating senescence induction and ameliorating OA development."
hTtps://www.miragenews.com/sirtuin-6-activation-reverses-age-related-dna-1147181/
Yep, we just need Eric to sprinkle a bit of joy....Final invivo results, grants/funding, a Major investor and or JV partner , C'mon Eric, when you’re ready!!! :-)))
Unless Eric has a nice big Christmas pressie for us.....Ho ho ho.....Gla holders ;-)
0 0 0
GenFlow Biosciences
1,349 followers
14h
According to Tim Opler, a managing director in Stifel's global healthcare group, the biotech industry is on a trajectory of historic outperformance and innovation, especially in areas like combating aging and enhancing human health - core focuses of our work.
Key points:
1️⃣ Biotech investments have consistently outperformed the market. This trend shows no signs of slowing down, making it an attractive sector for long-term investment.
2️⃣ The pace of biomedical innovation is not just keeping up; it's accelerating! This opens up countless opportunities in healthcare and beyond.
3️⃣ Biotech is poised to be a major driver of economic growth globally.
4️⃣ From medical spend to pharma dynamics, the landscape is evolving. Biotech stands at the forefront of this transformation, promising a future where medical innovation alters our civilization.
💡 The message is clear: we are on the cusp of a 'Biotech Century.' The sector holds immense promise for investors, innovators, and society at large.
It's a realm where scientific curiosity meets groundbreaking advancements, potentially changing the way we live and thrive.
Learn more here: htTps://loom.ly/uh0pGy8 #healthspan #longevity #Biotech #genetherapy
An early show of hands, Genflow next ??? Gla ;-)
Extended Longevity Enters XPRIZE Healthspan Competition with Groundbreaking Anti-Aging Solutions
December 12, 2023 10:08 AM Eastern Standard Time
KULA, Hawaii--(BUSINESS WIRE)--Extended Longevity, a pioneering company in the field of longevity and anti-aging, is proud to announce its entry into the prestigious $101 million dollar XPRIZE Healthspan competition. This move marks a significant milestone in Extended Longevity's commitment to revolutionize the way we understand and approach aging.
htTps://www.businesswire.com/news/home/20231212060240/en/Extended-Longevity-Enters-XPRIZE-Healthspan-Competition-with-Groundbreaking-Anti-Aging-Solutions
Lol Northeast, I should very much think so, inbthat Genflow have highlited it twice in the last week on Linkden, although plenty of other grants/funding/investments just as likely from those who can see the bigger picture...Excitement building....Ho ho ho :-)
GenFlow Biosciences
1,347 followers
5d
The XPRIZE Healthspan competition is a 7-year, $101 million global contest aimed at revolutionizing human aging. It focuses on creating proactive, accessible therapies that reduce the risk of chronic age-related diseases, improve healthspan, and extend quality of life into later years. The competition seeks to shift from traditional medicine's reactive approach to a more proactive one, aiming to improve overall health quality and reduce healthcare costs associated with aging. For more details: https://loom.ly/6xVoHz0 #XPRIZE #healthspan #longevity #genetherapy
Ps I reckon Eric has news up his sleeve. GLA :-)
"Genflow is at the forefront with our promising GF-1002 treatment, showcasing adipogenic, anti-fibrotic, and anti-tumoral effects. This progress is significant in a market expected to reach $27.2B by 2029."
Amazing what positive Phase 2 results can do. Gla :-)
https://longevity.technology/news/eyepoint-raises-230-million-following-positive-amd-trial-results/amp/
GenFlow Biosciences
1,347 followers
2h
A recent Fierce Pharma article highlights the burgeoning market for NASH (Non-Alcoholic Steatohepatitis) treatments, a crucial area where GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) is actively contributing. As the NASH patient population rapidly grows, the need for effective therapies becomes increasingly urgent. Genflow is at the forefront with our promising GF-1002 treatment, showcasing adipogenic, anti-fibrotic, and anti-tumoral effects. This progress is significant in a market expected to reach $27.2B by 2029. We're proud to contribute to a future where NASH patients have hope for better treatments. Read more: https://loom.ly/tjXfrkE Discover more about our clinical programs: https://loom.ly/kKTAoxM #GenflowBiosciences #NASH #livertreatment
Loads of reasons why a few punters might want sell out at this time of year, and you have to feel for those who had been selling out at the rockbottom low at DGI , prior to their news....Gla holders!!! :-)
Hopefully so Porter, and 2024 could be a stellar year for all invested. In the meantime more compelling research on Sirt6, hot off the press. Gl :-)
https://www.lifespan.io/news/repairing-dna-with-sirtuins-for-arthritis/
C'mon Eric, any news for Christmas as news on lgrants/funding were expected soon along with 4 final invivo studies from Genflows High profile academic collaborations....news of a Major investor and or JV partner highly possible at anytime. :-)
28/9/23
The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.
......
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
The Future Of Aging – A Conversation With Dr. Eric Leire
Nov 6, 2023 | The Futurist Society
Many of us strive towards living long lives; but just as health risks grow as we age,
hTtps://www.thefuturistsociety.net/the-future-of-aging-a-conversation-with-dr-eric-leire
Plenty of dosh flowing into the longevity space, fingers crossed Genflow's turn soon. Gla holders , let's hope Eric has a flow of good news to report into Christmas and the New Year.:-)
Biolexis lands $10m to advance metabolic drug program with longevity potential
2 HOURS AGO
hTtps://longevity.technology/news/biolexis-lands-10m-to-advance-metabolic-drug-program-with-longevity-potential/amp/
GenFlow Biosciences
1,340 followers
15m
ArrivoBio has secured $45 million in Series B financing to progress its novel drug candidates, including SP-624 for major depressive disorder (MDD). SP-624, a groundbreaking treatment, activates the SIRT6 enzyme, offering a new approach to managing MDD. At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) we are pioneering research on SIRT6 to unlock its potential to extend healthspan and fight aging. Our dedicated efforts in this domain underscore the importance of genetic research in tackling major health issues like aging and mental health. Read about it here: https://loom.ly/GBsJLeY #SIRT6 #healthspan #longevity #mentalhealth
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline | BioSpacebiospace.com
Good Morning Porter, not me but i've had a couple of top ups this week in anticipation of imminent news from Eric, and very much looking forward to a stellar 2024 for Genflow. Gl ;-)
Get UP there!!! Gla holders...news from Eric on grants/funding expected soon along with 4 final invivo studies from Genflows High profile academic collaborations....news of a Major investor and or JV partner at anytime. :-)
28/9/23
The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.
......
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
But even the companies regarded as the cream-of-crop are at a disadvantage…
They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”
Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.
This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…
If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.
Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.
It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.
Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price
News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.
This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.
That is why I am recommending readers take a close look at it right now.
The company is currently eyeing a listing in other markets and a US listing may be on the horizon.
If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.
A company I believe is set to explode and has the potential to rise significantly in the near term.
What justifies such a bold prediction?
This company may hold the keys to the cure for aging...
The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.
Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*
The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.
But before I go any further, let me ask you something…
Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?
According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.
With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.
But backing from big names isn’t the only ace up the sleeve of Altos Labs…
The company has built an executive dream team of industry experts and scientific luminaries.
Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.
What is reprogramming and why is it important you might ask?
Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.
Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?
Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.
With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”
But what does all of this have to do with Genflow Biosciences potentially significant rise in value?
I’m going to tell you, but first, let’s get some background.
Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).
Okay, but why should we expect such sudden exponential growth.
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...
To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.
But even the companies regarded as the cream-of-crop are at a disadvantage…